I12.9 Insurance Policy Changes

ICD-10 I12.9 is officially defined as "Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease." code I12.9 is referenced in 7 tracked payer policy changes from UnitedHealthcare, Florida Blue, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code I12.9 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

UnitedHealthcare · Effective Dec 1, 2026Medium impact
Intravenous Iron Replacement Therapy (Feraheme ® , Injectafer ® , & Monoferric ® )
UnitedHealthcare Community Plan of Indiana revised its Medicaid medical policy for Feraheme (ferumoxytol), Injectafer (ferric carboxymaltose), and Monoferric (ferric derisomaltose). Coverage is now described as proven for iron deficiency anemia without CKD and for iron deficiency anemia with CKD but without ESRD, and Injectafer is covered for iron deficiency in adults with NYHA class II/III heart failure to improve exercise capacity when all listed criteria are met; the policy also adds definitions and ICD-10 codes for these indications and removes the language excluding Indiana.
Florida Blue · Effective Jul 1, 2026High impact
Every Reading Counts: Your Contribution to Better Blood Pressure Outcomes
Florida Blue has issued updated guidance on blood pressure management documentation and coding for HEDIS reporting. Providers must now document exact blood pressure readings (no rounding or ranges), utilize specific CPT II codes (3074F-3080F) based on systolic/diastolic thresholds, and assign appropriate ICD-10 codes for hypertensive conditions. This change emphasizes detailed documentation to support quality measure compliance and care management targeting.
Medicare/CMS - Transmittals · Effective Oct 28, 2025Medium impact
R13802CP: NCD 20.40- Renal Denervation (RDN) for Uncontrolled Hypertension
Medicare covers radiofrequency renal denervation and ultrasound renal denervation (collectively RDN) for uncontrolled hypertension under Coverage with Evidence Development, for dates of service on or after October 28, 2025. RDN for uncontrolled hypertension is not covered for patients outside of a CMS-approved study. Institutional and professional claims must carry specific ICD-10-PCS, CPT, HCPCS, ICD-10-CM, value code, condition code, modifier and place of service data.
Aetna · Identified Oct 7, 2026Medium impact
Brain Natriuretic Peptide Testing (CPB 0618, reviewed 2026-09-29)
Aetna considers measurement of plasma brain natriuretic peptide (BNP) medically necessary to differentiate dyspnea due to heart failure from pulmonary disease, to determine prognosis or severity in chronic heart failure, to screen for heart failure annually in adults with diabetes mellitus, to measure upon hospital admission and before discharge in acutely decompensated heart failure, for preoperative cardiac risk assessment before elevated-risk noncardiac surgery in members with known cardiovascular disease, age 65 or older, or age 45 or older with cardiovascular symptoms, and as an adjunct test for risk stratification of Stage C aortic stenosis. Serial BNP and NT-proBNP measurements and the other uses listed in the policy, such as diagnosing Kawasaki disease, are considered experimental, investigational, or unproven. CPT 83880 is covered when the selection criteria are met, except as a cardiovascular biomarker in healthy normal subjects and for identifying stress-induced myocardial ischemia.
Aetna · Identified Oct 2, 2026Medium impact
Extracorporeal Shock-Wave Therapy for Musculoskeletal Indications and Soft Tissue Injuries (CPB 0649, reviewed 2026-09-14)
Aetna clinical policy bulletin 0649 (reviewed September 14, 2026) considers extracorporeal shock-wave therapy medically necessary only for calcific tendinopathy of the shoulder that has lasted at least 6 months, has a calcium deposit of 1 cm or more, and has not responded to conservative care. It lists many other musculoskeletal, pain, wound and scar indications as experimental or not covered. The source gives a review date but no effective date, so confirm current applicability before changing workflows.
Aetna · Identified Aug 14, 2026Medium impact
Intensive Cardiac Rehabilitation Programs (CPB 0267, reviewed 2026-05-14)
Aetna considers intensive cardiac rehabilitation programs (the Benson-Henry Institute Cardiac Wellness Program, the Ornish cardiac treatment program and the Pritikin Program) medically necessary as an alternative to traditional Phase II cardiac rehabilitation for members who meet the cardiac rehabilitation criteria, limited to 72 one-hour sessions, up to 6 per day, over a period of up to 18 weeks. Virtual delivery by real-time audio and video (excluding audio-only) is considered medically necessary when the telehealth program and member criteria are met, but hospital outpatient departments are not eligible for virtual telehealth services. Intensive cardiac rehabilitation is considered experimental, investigational or unproven for diabetes, hyperlipidemia, prostate cancer, metabolic syndrome and all other indications where effectiveness has not been established.
Aetna · Identified Aug 15, 2026Low impact
Extracorporeal Shock-Wave Therapy for Musculoskeletal Indications and Soft Tissue Injuries (CPB 0649, reviewed 2025-10-02)
This is Aetna Clinical Policy Bulletin 0649, reviewed October 2, 2025 and first found by PolicyChanges in August 2026, so it is historical material and the current version should be confirmed before acting. Aetna covers extracorporeal shock-wave therapy only for calcific tendinopathy of the shoulder with a calcium deposit of at least 1 cm lasting 6 months or more after conservative care has failed, and lists dozens of other musculoskeletal, wound and medical uses as experimental, investigational or unproven.

Watch I12.9

Get one email when a payer policy names I12.9, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code I12.9?

There are 7 tracked policy changes affecting code I12.9, including updates from UnitedHealthcare, Florida Blue, Medicare/CMS - Transmittals. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code I12.9?

Payers that have issued tracked updates for code I12.9 include: UnitedHealthcare, Florida Blue, Medicare/CMS - Transmittals, Aetna.

How do I get notified when code I12.9 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code I12.9. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code I12.9?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Intravenous Iron Replacement Therapy (Feraheme ® , Injectafer ® , & Monoferric ® )

Every Reading Counts: Your Contribution to Better Blood Pressure Outcomes

R13802CP: NCD 20.40- Renal Denervation (RDN) for Uncontrolled Hypertension

Brain Natriuretic Peptide Testing (CPB 0618, reviewed 2026-09-29)

Extracorporeal Shock-Wave Therapy for Musculoskeletal Indications and Soft Tissue Injuries (CPB 0649, reviewed 2026-09-14)

Intensive Cardiac Rehabilitation Programs (CPB 0267, reviewed 2026-05-14)

Extracorporeal Shock-Wave Therapy for Musculoskeletal Indications and Soft Tissue Injuries (CPB 0649, reviewed 2025-10-02)

What insurance policy changes affect code I12.9?

Which payers have updated policy for code I12.9?

How do I get notified when code I12.9 policy changes?

Why do payers change policies for code I12.9?